{
    "clinical_study": {
        "@rank": "75526", 
        "arm_group": [
            {
                "arm_group_label": "ALXN1007", 
                "arm_group_type": "Experimental", 
                "description": "Infusion of ALXN1007"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Infusion placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and\n      pharmacodynamics (PD) of multiple intravenous (IV) doses of ALXN1007 in healthy male and\n      female subjects."
        }, 
        "brief_title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy male or female (not of childbearing potential) subjects \u226525 and \u226455 years old.\n\n        2. QTcF \u2264450 msec and \u2264470 for females. 3. Willing and able to give written informed\n        consent and comply with the study visit schedule.\n\n        4. Male subject and his female spouse/partner who is of childbearing potential must be\n        using highly effective congraception1 consisting of two forms of birth control (at least\n        one of which must be a barrier method) starting at Screening and continuing until the end\n        of study.\n\n          1. Highly effective contraception is defined as:\n\n               -  Established use of oral, injected or implanted hormonal methods of\n                  contraception.\n\n               -  Placement of an intrauterine device or intrauterine system.\n\n               -  Barrier methods of contraception: condom or occlusive cap (diaphragm or\n                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.\n\n                  5. Male subjects must not donate sperm starting at Screening until the end of\n                  study.\n\n                  6. Documented vaccination with meningococcal conjugate vaccine (MCV4) at least\n                  14 days and not more than 5 years, prior to dosing.\n\n        Exclusion Criteria:\n\n        Female subjects of childbearing potential, including any female who has experienced\n        menarche and who has not undergone successful surgical sterilization (hysterectomy,\n        bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal.\n        Postmenopausal is defined as:\n\n          -  Amenorrhea \u2265 12 consecutive months without another cause and a documented serum\n             follicle stimulating hormone (FSH) level >35 mIU/mL or\n\n          -  Female subjects with irregular menstrual periods and a documented serum FSH level >\n             35 mIU/mL.\n\n          -  Women on hormone replacement therapy (HRT). Women who are using oral contraceptives,\n             other hormonal contraceptives (i.e., vaginal products, skin patches, or implanted or\n             injectable products), or mechanical products such as an intrauterine device or\n             barrier methods (i.e., diaphragm, condoms, spermicides) to prevent pregnancy, or are\n             practicing abstinence or where their partner is sterile (e.g., vasectomy) should be\n             considered to be of childbearing potential.\n\n             2. Positive serum pregnancy test at Screening or Day -1. 3. Serum creatinine great\n             than the upper limit of normal (ULN) of the testing laboratory at Screening and Day\n             -1.\n\n             4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >ULN of the\n             testing laboratory at Screening and Day -1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883544", 
            "org_study_id": "ALXN1007-US-HV-102"
        }, 
        "intervention": {
            "arm_group_label": [
                "ALXN1007", 
                "placebo"
            ], 
            "intervention_name": "ALXN1007", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "ALXN1007", 
            "Healthy Male and Female Subjects"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }, 
                "name": "PAREXEL Baltimore EPCU"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Blinded, Placebo-Controlled, Multiple IV Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the safety and tolerability of multiple, IV doses of ALXN1007 in healthy male and female subjects as assessed by physical exam, vital signs, electrocardiogram (ECG), immunogenicity, laboratory analysis, and assessment of adverse events (AEs", 
            "safety_issue": "Yes", 
            "time_frame": "90 days follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883544"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alexion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}